However, except for one explorative study describing reduced inflammatory markers in COVID-19 patients treated with immunomodulatory drugs as a secondary endpoint [19], no studies have related overall suppression of PCT and CRP to their ability to detect secondary bacterial infections in COVID-19 patients. The gene discussed is CRP; the disease is bacterial infectious disease.